The Cooper Companies, Inc. $COO Shares Purchased by J.Safra Asset Management Corp

J.Safra Asset Management Corp increased its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 204.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 506 shares of the medical device company’s stock after acquiring an additional 340 shares during the period. J.Safra Asset Management Corp’s holdings in Cooper Companies were worth $36,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Zions Bancorporation National Association UT acquired a new stake in Cooper Companies during the first quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new stake in Cooper Companies during the first quarter worth about $40,000. Larson Financial Group LLC grew its holdings in Cooper Companies by 1,071.0% during the first quarter. Larson Financial Group LLC now owns 726 shares of the medical device company’s stock worth $61,000 after acquiring an additional 664 shares during the period. HM Payson & Co. grew its holdings in Cooper Companies by 147.4% in the first quarter. HM Payson & Co. now owns 893 shares of the medical device company’s stock valued at $75,000 after purchasing an additional 532 shares during the period. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Cooper Companies by 33.7% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,191 shares of the medical device company’s stock valued at $85,000 after purchasing an additional 300 shares during the period. 24.39% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius acquired 2,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was purchased at an average cost of $68.39 per share, for a total transaction of $136,780.00. Following the completion of the transaction, the director owned 5,777 shares in the company, valued at approximately $395,089.03. This trade represents a 52.95% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Daniel G. Mcbride acquired 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average price of $65.04 per share, with a total value of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares of the company’s stock, valued at $4,105,324.80. The trade was a 4.99% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 17,975 shares of company stock worth $1,216,346. 1.98% of the stock is currently owned by company insiders.

Cooper Companies Stock Performance

Shares of NASDAQ:COO opened at $71.21 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The business’s 50 day moving average price is $69.42 and its 200-day moving average price is $73.46. The firm has a market capitalization of $14.16 billion, a PE ratio of 35.08, a P/E/G ratio of 1.82 and a beta of 1.02. The Cooper Companies, Inc. has a 1 year low of $61.78 and a 1 year high of $109.37.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.03. The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.The business’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, equities research analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Cooper Companies announced that its board has approved a share buyback plan on Wednesday, September 17th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical device company to buy up to 15.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have commented on COO shares. Needham & Company LLC reissued a “buy” rating and issued a $94.00 price objective on shares of Cooper Companies in a report on Thursday, August 28th. BNP Paribas Exane raised Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Tuesday, July 22nd. Wall Street Zen lowered Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Morgan Stanley set a $76.00 price objective on Cooper Companies and gave the company an “equal weight” rating in a report on Thursday, August 28th. Finally, Stifel Nicolaus dropped their price objective on Cooper Companies from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and an average target price of $84.77.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.